Here's why: The top 5 diagnostics-related venture capital deals in the 2014 second quarter are much more robust than those from the previous quarter, reflecting a larger med tech trend that produced a healthy hike in both deal value and volume versus Q1.
We all know the life sciences industry produces plenty of hype about new diagnostic advances, cutting-edge treatments and lifesaving surgeries. Many are profoundly amazing and life-changing inventions that have saved countless lives. But the truth is that much of patient diagnosis and care remains guesswork, trial, error and hope. Read more >>
POPULAR COMMENT THREADS
Qiagen aims to develop new tests to target blood cancer patients who would benefit most from a particular treatment that hits a specific gene mutation. The plan could lead to new companion diagnostic tests for related drugs now under development.
OncoCyte is vastly expanding testing of its urine-based bladder cancer diagnostic with the launch of a multisite clinical trial involving up to 1,200 patient samples.
A global team of researchers believe they've developed a blood test that could prevent neural tube birth defects such as spina bifida.
This summer, venture investment trends have given the medical diagnostics industry reason for at least a little optimism.
California's Epic Sciences nailed down $30 million in new financing it plans to use to commercialize tests that can detect circulating tumor cells during a patient's treatment, allowing for a more personalized cancer treatment as the disease evolves.
Japanese tech giant Konica Minolta sealed an agreement with a New Jersey diagnostics outfit to develop a test that can rapidly detect early cardiac muscle tissue damage after heart attacks strike.
From Our Sister Sites
In this week's EuroBiotech Report, the last week of July was a massive one for European biotech IPOs, with BioBlast Pharma, Innocoll, Macrocure, Mapi Pharma and VBL Therapeutics all heading to the Nasdaq. All of the companies struggled though. And more.
Quintiles hit the $1 billion revenue mark for a third straight quarter, dialing up its full-year guidance as it expands its share of the global outsourcing market.